Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALIZADE: Zetomipzomib in Active Lupus Nephritis
2022-502227-22-00Phase 2Completed
- Sponsor
- Kezar Life Sciences
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial of zetomipzomib in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (3 arms), sponsored by Kezar Life Sciences. Primary endpoint: Complete renal response (CRR) at Week 37. Started Oct 2023; status: completed.
02
Drugs
zetomipzomib
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2022-502227-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502227-22-00.